Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis-Reference-Cited by-同舟云学术

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis

Published:2022-02-07 Issue: Volume: Page:
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

McInnes Iain B.¹^ORCID,Rahman Proton²,Gottlieb Alice B.³,Hsia Elizabeth C.⁴,Kollmeier Alexa P.⁵,Xu Xie L.⁵,Jiang Yusang⁶,Sheng Shihong⁶,Shawi May⁷,Chakravarty Soumya D.⁸^ORCID,Heijde Désirée⁹,Mease Philip J.¹⁰^ORCID

Affiliation:

1. University of Glasgow Glasgow UK

2. Memorial University of Newfoundland St. Johns Newfoundland Canada

3. Icahn School of Medicine Mt. Sinai New York New York

4. Janssen Research & Development Spring House, Pennsylvania, and University of Pennsylvania Philadelphia Pennsylvania

5. Janssen Research & Development, LLC San Diego California

6. Janssen Research & Development Spring House Pennsylvania

7. Janssen Pharmaceutical Companies of Johnson & Johnson Horsham Pennsylvania

8. Janssen Scientific Affairs Horsham, Pennsylvania, and Drexel University College of Medicine Philadelphia Pennsylvania

9. Leiden University Medical Center Leiden The Netherlands

10. Swedish Medical Center/Providence St. Joseph Health and University of Washington Seattle Washington

Funder